Meridian Management’s AstraZeneca AZN Stock Holding History

Meridian Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,687	Closed	-$224K	–	74
2022 Q1	$224K	Buy	+1,687	New	+$202K	0.07%	80

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Meridian Management's AZN Position: Q2 2022 in Review

Meridian Management sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 1,687 shares — an estimated $224K sold.

Meridian Management first reported a position in AZN in Q1 2022 and held it in 1 quarter. The position peaked at $224K in Q1 2022. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Meridian Management reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Meridian Management sold 1,687 AstraZeneca shares in Q2 2022, an estimated $224K.
Meridian Management first reported a position in AstraZeneca in Q1 2022 and held it in 1 quarter.
Meridian Management's AstraZeneca position peaked at $224K in Q1 2022.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Meridian Management's 13F filing for Q2 2022, filed 5 Aug 2022.